Drug class
Nitrosourea alkylating antineoplastic agent
Mechanism of action
Generates reactive alkylating intermediates that form DNA crosslinks and interfere with DNA replication and transcription, causing tumour-cell death.
General use cases
- Treatment of selected malignant melanoma and primary brain tumours, including glioblastoma, in countries where fotemustine is authorised; clinical use and approved lines of therapy are jurisdiction-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
